NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.
NKGen Biotech has raised $2.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2025.
NKGen Biotech's investors include Gaingels, HekaBio, Paul Y. Song.
NKGen Biotech is headquartered in Santa Ana, United States.
NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.
NKGen Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NKGen Biotech — Funding & Investors." VCBacked, July 14, 2025, https://www.vcbacked.co/company/nkgen-biotech. Accessed August 14, 2026.
VCBacked. (2025). NKGen Biotech — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/nkgen-biotech
{{cite web |title=NKGen Biotech — Funding & Investors |url=https://www.vcbacked.co/company/nkgen-biotech |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated